Journal
HEALTH AFFAIRS
Volume 30, Issue 12, Pages 2259-2268Publisher
PROJECT HOPE
DOI: 10.1377/hlthaff.2010.0637
Keywords
-
Funding
- Center for Comparative Effectiveness Research in Cancer Genomics through National Cancer Institute, National Institutes of Health [5UC2CA148570-02]
Ask authors/readers for more resources
The use of biomarkers to personalize cancer treatment-identifying discrete genes, proteins, or other indicators that can differentiate one type of cancer from another and enable the use of highly tailored therapies-offers tremendous potential for improved outcomes and lower treatment costs. However, the rapid development of cancer biomarker, or genomic, tests-combined with a paucity of evidence to support the effectiveness of the tests-presents a challenge for patients, clinicians, and other stakeholders. In this article we propose that comparative effectiveness research be used to strengthen what is now a haphazard process for developing and marketing cancer biomarker tests. We suggest novel funding approaches and a systematic process for moving from regulatory approval to the generation of evidence that meets the needs of stakeholders and, ultimately, patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available